Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer

Cancer Microenvironment

Volumn 8, Issue 1, 2015, Pages 45-56

  Baker, Amanda F ^a   Malm, Scott W ^a   Pandey, Ritu ^a   Laughren, Cindy ^a   Cui, Haiyan ^a   Roe, Denise ^b   Chambers, Setsuko K ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Hypoxia regulated gene panel; Ovarian cancer; Tumor microenvironment

Indexed keywords

ADRENOMEDULLIN; ALDOLASE A; ALPHA POLYPEPTIDE 1; CARBONATE DEHYDRATASE IX; COMPLEMENTARY DNA; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE TRANSPORTER 1; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; MYC PROTEIN; N MYC DOWNSTREAM REGULATED 1; PHOSPHOGLYCERATE MUTASE; PHOSPHOGLYCERATE MUTASE 1; PIMONIDAZOLE; POLYPEPTIDE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADRENOMEDULLIN GENE; ALDOLASE A GENE; ALPHA POLYPEPTIDE 1 GENE; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARBONIC ANHYDRASE 9 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; GLUCOSE TRANSPORTER 1 GENE; HEY CELL LINE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA REGULATED GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LACTATE DEHYDROGENASE A GENE; MOUSE; N MYC DOWNSTREAM REGULATED 1 GENE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVCAR 3 CELL LINE; PHENOTYPE; PHOSPHOGLYCERATE MUTASE 1 GENE; PRIORITY JOURNAL; PROLYL 4 HYDROXYLASE GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR GENE; TUMOR XENOGRAFT; UPREGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE;

EID: 84930088631     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-015-0166-x     Document Type: Article

References (39)

1. Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107(6):1053–1062
2. Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40
3. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7(6):1661–1668
4. Hazelton DA, Hamilton TC (1999) Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1(1):59–63
5. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS (2010) Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16(21):5320–5328
6. Bamias A, Pignata S, Pujade-Lauraine E (2012) Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 84(3):314–326
7. Khosravi-Shahi P, Cabezon-Gutierrez L (2012) Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer. Anticancer Agents Med Chem 12(8):982–987
8. Betts GN, Eustace A, Patiar S, Valentine HR, Irlam J, Ramachandran A, Merve A, Homer JJ, Moller-Levet C, Buffa FM, Hall G, Miller CJ, Harris AL, West CM (2013) Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. Eur J Cancer 49(1):156–165
9. Williams E, Martin S, Moss R, Durrant L, Deen S (2012) Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. Virchows Arch 461(1):33–39
10. Milosevic M, Fyles A, Hedley D, Hill R (2004) The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14(3):249–258
11. Le QT, Courter D (2008) Clinical biomarkers for hypoxia targetin. Cancer Metastasis Rev 27(3):351–362
12. Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167(2):127–145
13. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795(2):162–172
14. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van d, V, Brown PO (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3(3):e47
15. Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102(2):428–435
16. Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM (2007) Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Investig 87(10):979–997
17. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25(4):402–408
18. Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167(2):127–145
19. Shin KH, Az-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC (2007) Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 6(1):70–75
20. Brahimi-Horn MC, Bellot G, Pouyssegur J (2011) Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 21(1):67–72
21. Chen JL, Merl D, Peterson CW, Wu J, Liu PY, Yin H, Muoio DM, Ayer DE, West M, Chi JT (2010) Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet 6(9):e1001093
22. Mayer A, Vaupel P (2013) Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol 789:203–209
23. de Saedeleer CJ, Copetti T, Porporato PE, Verrax J, Feron O, Sonveaux P (2012) Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells4. PLoS One 7(10):e46571
24. Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, Jouve E, Lis R, Thiery JP, Querleu D, Rafii A (2011) Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One 6(12):e28561
25. Fong MY, McDunn J, Kakar SS (2011) Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 6(5):e19963
26. Yu L, Deng L, Li J, Zhang Y, Hu L (2013) The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 128(2):391–396
27. Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A (2012) Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol 2012:245756
28. Kim K, Park WY, Kim JY, Sol MY, Shin DH, Park DY, Lee CH, Lee JH, Choi KU (2012) Prognostic relevance of the expression of CA IX, GLUT-1, and VEGF in ovarian epithelial cancers. Korean J Pathol 46(6):532–540
29. Cho H, Lee YS, Kim J, Chung JY, Kim JH (2013) Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Investig 31(9):607–615
30. Airley R, Evans A, Mobasheri A, Hewitt SM (2010) Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 192(3):133–138
31. Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Li-Fehmi R (2011) Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 121(1):181–186
32. Hata K, Takebayashi Y, Akiba S, Fujiwaki R, Iida K, Nakayama K, Nakayama S, Fukumoto M, Miyazaki K (2000) Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 6(10):867–872
33. Baranello C, Mariani M, Andreoli M, Fanelli M, Martinelli E, Ferrandina G, Scambia G, Shahabi S, Ferlini C (2012) Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo? 1. PLoS One 7(7):e40678
34. Frede S, Freitag P, Otto T, Heilmaier C, Fandrey J (2005) The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation 2. Cancer Res 65(11):4690–4697
35. Lv XH, Chen JW, Zhao G, Feng ZZ, Yang DH, Sun WW, Fan JS, Zhu GH (2012) N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J Cancer Res Clin Oncol 138(10):1703–1715
36. Wang B, Li J, Ye Z, Li Z, Wu X (2014) N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer. Oncol Rep 31(5):2279–2285
37. Choschzick M, Oosterwijk E, Muller V, Woelber L, Simon R, Moch H, Tennstedt P (2011) Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459(2):193–200
38. Hunakova L, Bodo J, Chovancova J, Sulikova G, Pastorekova S, Sedlak J (2007) Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma 54(6):541–548
39. Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivela J, Pastorekova S, Pastorek J, Waheed A, Sly WS, Puistola U, Parkkila S (2006) Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49(6):594–602